Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
October 01, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
September 18, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
September 04, 2024 04:01 ET
|
Mainz BioMed NV
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
July 25, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
July 09, 2024 03:01 ET
|
Mainz BioMed NV
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update
July 02, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Provides Half Year 2024 Corporate Update -
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 03, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Reports Results of 2024 Annual General Meeting
May 31, 2024 17:01 ET
|
Mainz BioMed NV
Mainz Biomed Reports Results of 2024 Annual General Meeting
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
May 28, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 20, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial